European Journal of Heart Failure Publishes Pre-Specified Sub-Group Analysis of Heart Failure Patients With Hyperkalemia From Phase 3 Trial of Patiromer FOS

By: via Benzinga
Relypsa Inc. (NASDAQ: RLYP), a biopharmaceutical company, today announced that results of a pre-specified sub-group analysis from the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.